

# Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab)

Recombinant Antibody

Catalog # APR10088

## Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	<a href="#">P20273</a>
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	95348


## Additional Information

Target/Specificity	Siglec-2 / CD22
Endotoxin Conjugation	Unconjugated
Expression system	CHO Cell
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.


## Protein Information

Name	CD22 {ECO:0000303 PubMed:1691828, ECO:0000312 HGNC:HGNC:1643}
Function	<p>Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed:<a href="#">34330755</a>, PubMed:<a href="#">8627166</a>). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed:<a href="#">20172905</a>). Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling (PubMed:<a href="#">8627166</a>). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed:<a href="#">20516366</a>).</p>
Cellular Location	<p>Cell membrane; Single-pass type I membrane protein</p> <p>B-lymphocytes.</p>


Images



Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab) is more than 97.02% ,determined by SEC-HPLC.



Immobilized human CD22 His at 2 µg/mL can bind Anti-Siglec-2 / CD22 Reference Antibody (pinatuzumab), EC50=0.008601 µg/mL

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.